SCHEMBL9372532

SCHEMBL9372532

N[C@@H](CCC(=O)NCCS)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 2/20 0.51
▸ GSTK1 Q9Y2Q3 1/20 0.51
▸ GRM8 O00222 1/20 0.50
▸ GRM6 O15303 1/20 0.50
▸ GRIN2D O15399 1/20 0.50
▸ GRIN3B O60391 1/20 0.50
▸ GSR P00390 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ GRIK1 P39086 1/20 0.50
▸ GRM5 P41594 1/20 0.50
▸ GRIA1 P42261 1/20 0.50
▸ GRIA2 P42262 1/20 0.50
▸ GRIA3 P42263 1/20 0.50
▸ SLC1A3 P43003 1/20 0.50
▸ SLC1A2 P43004 1/20 0.50
▸ SLC1A1 P43005 1/20 0.50
▸ GRIA4 P48058 1/20 0.50
▸ GRIN1 Q05586 1/20 0.50
▸ GRIN2A Q12879 1/20 0.50
▸ GRIK2 Q13002 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28634437 1.00 PTGS1 (0.51) PTGS1GSTK1GRM8GRM6GRIN2D
SCHEMBL29590846 0.88 SLC1A1 (0.58) PTGS1GSTK1GRM8GRM6GRIN2D
SCHEMBL1768542 0.83 GSR (0.52) PTGS1GSTK1GRM8GRM6GRIN2D
SCHEMBL1768540 0.83 GSR (0.52) PTGS1GSTK1GRM8GRM6GRIN2D
SCHEMBL8041596 0.83 GRM8 (0.63) PTGS1GSTK1GRM8GRM6GRIN2D
SCHEMBL1374853 0.83 SLC1A1 (0.52) PTGS1GSTK1GRM8GRM6GRIN2D
SCHEMBL1512875 0.83 SLC1A1 (0.52) PTGS1GSTK1GRM8GRM6GRIN2D
SCHEMBL8041593 0.83 GRM8 (0.63) PTGS1GSTK1GRM8GRM6GRIN2D
SCHEMBL18656205 0.82 OTC (0.59) PTGS1GSTK1GRM8GRM6GRIN2D
SCHEMBL25357016 0.81 ALOX15 (0.64) PTGS1GSTK1GRM8GRM6GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11357750-B2 Cysteamine prodrugs CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2022-06-14 — — US disclosed
EP-0280741-B1 MITOMYCIN DERIVATIVES KYOWA HAKKO KOGYO KK (JP) 1994-12-07 — — EP disclosed
US-5103018-A Antitumor agent; side effect reduction KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) 1992-04-07 — — US disclosed
EP-0280741-A1 MITOMYCIN DERIVATIVES KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) 1988-09-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11357750-B2 Cysteamine prodrugs SLC7A11, CTH, CBS PTGS1 684/4885GSTK1 479/4885GRM8 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback